Chimeric TNT-3/human β-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT)

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 3, 2003, Pages 339-353

  Biela, Barbara H ^a   Khawli, Leslie A ^a   Hu, Peisheng ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antibody directed enzyme prodrug therapy (ADEPT); Antibody enzyme fusion proteins; Chimeric antibodies; Doxorubicin; Tumor necrosis therapy; glucuronidase

Indexed keywords

BETA GLUCURONIDASE; CHIMERIC PROTEIN; CYTOTOXIC AGENT; DOXORUBICIN; GLUCURONIDE; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PRODRUG; REAGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS THERAPY 3 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; BODY DISTRIBUTION; CATALYSIS; CELL DEGENERATION; CLONING VECTOR; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG BINDING; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LOCALIZATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LUNG CARCINOMA; MOUSE; NONHUMAN; OUTCOMES RESEARCH; PHARMACOKINETICS; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; TECHNIQUE; TISSUE SPECIFICITY; TUMOR MODEL; TUMOR NECROSIS;

EID: 0042242757     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322285099     Document Type: Article

References (50)

1. Haskell CM. Principles of cancer chemotherapy. In: Haskell (ed.), Cancer Treatment. Saunders, Philadelphia, 1985, pp. 1-21.
2. Young RC. The clinical problems. In: R.F. Ozols (ed.), Drug Resistance in Cancer Therapy. Kluwer Academic Publishers: Boston, 1989, pp. 1-25.
3. Calabresi P, Welch AD. Cytotoxic drugs, hormones and radioactive isotopes. In: Goodman L.S., Gilman A., (eds.), The pharmacological basis of therapeutics. Macmillan, New York, 1994, pp. 13-45.
4. Hudson P. Recombinant antibody constructs in cancer therapy. Current Opinion Immunol 1999;11:548-557.
5. Bagshawe KD. Antibody directed enzymes revive anticancer prodrug concept. Br J Cancer 1987;56:531-540.
6. Hornick JL, Sharifi J, Khawli LA, Hu P, Bao WG, Allaudin MM, Mizokami MM, Epstein AL. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. J Nucl Med 2000;41:355-362.
7. Sharma SK, Bagshawe KD, Melton RG, Sherwood RF. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 1992;21:109-120.
8. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked, also the intravenous administration of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304.
9. Sharma SK. Immune response in ADEPT. Adv Drug Delivery Rev 1996;22:369-380.
10. Shipley JM, Grubb JH, Sly WS. The role of glycosylation and phosphorylation in the expression of active human b-glucuronidase. J Biol Chem 1993;268:12193-12198.
11. Sly WS, Quinton BA, McAlister WH, Rimoin DL. β-Glucuronidase deficiency: Report of clinical, radiologic and biochemical features of a new mucopolysaccharidosis. J Pediatrics 1973;82:249-257.
12. Levvy GA, Conchie J. β-Glucuronidase and the hydrolysis of glucuronides. In: GJ Dutton (ed.), Glucuronic acid, free and combined. Academic Press, New York, 1996, pp. 301-364.
13. Sedlacek HH, Seemann G, Hoffman D, Czech J, Lorenz P, Kolar C, Bosslet K. Antibodies as carriers of cytotoxicity. Karger, Basel, 1992, pp. 1-80.
14. Bosslet K, Czech J, Lorenz P, Sedlacek HH, Schuermann M, Seemann G. Molecular and functional characterization of fusion protein suited for tumour specific prodrug activation. Br J Cancer 1992;65:234-238.
15. Tannock IF, Ratin P. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373-4390.
16. Tietze LF, Newman M, Mollers T, Fischer T, Glusenkamp K-H, Rajewky M, Jahde E. Proton-mediated liberation of aldophosphamide from a non-toxic prodrug: A strategy for tumor selective activation of cytocidal drugs. Cancer Res 1989;49:4179-4184.
17. Weenen H, van Maanen JMS, McVie JG, Pinedo HM. Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′doxorubicin. Eur J Cancer Clin Oncol 1984;20:919-926.
18. Rivory LP, Robert J. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemoter Pharmacol 1995;36:176-179.
19. Connors TA, Knox RJ. Prodrugs in cancer chemotherapy. Stem Cells 1995;13:501-511.
20. Haisma HJ, Boven E, van Muijen M, de Jong J, van der Vijgh WFJ, Pinedo HM. A monoclonal antibody-b-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer 1992;66:474-478.
21. Houba PH, Leenders RGG, Boven E, Scheeren JW, Pinedo HM, Haisma HJ. Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in Antibody-Directed Enzyme Prodrug Therapy. Biochem Pharm 1996;52:455-463.
22. Albin N, Massaad L, Toussaint C, Mathieu M-C, Morizet J, Parise O, Gouyetter A, Chabot GG. Main drug-metabolizing enzyme system in human breast tumors and peritumoral tissues. Cancer Res 1993; 53:3541-3556.
23. Murdter TE, Sperker B, Kivisto KT, McClellan M, Fritz P, Friedel G, Linder A, Bosslet K, Toomes H, Dierkesmann R, Kroemer HK. Enhanced uptake of doxorubicin into bronchial carcinoma: β-Glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res 1997; 57:2440-2445.
24. Houba PHJ, Boven E, van der Meulen-Muileman IH, Leenders RGG, Scheeren JW, Pinedo HM, Haisma HJ. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody β-glucuronidase conjugate. Int J Cancer 2001;91:550-554.
25. Haisma HJ, Brakenhoff RH, van der Muelen-Muileman IH, Boven E. Construction and characterization of a fusion protein of single chain anti-carcinoma antibody 323/A3 and human β-glucuronidase. Cancer Immunol Immunother 1998;45:266-272.
26. Khawli LA, Biela BH, Hu P, Epstein AL. Fully stable, genetically-engineered Fab and F(ab′)2 fragments of the chimeric TNT-3 antibody produced in a mammalian expression system. Hybridoma Hybridomics 2002;21:11-18.
27. Oshima A, Kyle JW, Miller RD, Hoffman JW, Powell PP, Grubb JH, Sly SW, Tropak M, Guise KS, Gravel RA. Cloning, sequencing and expression of cDNA for human beta-glucuronidase. Proc Natl Acad Sci. USA 1987;84:685-689.
28. Schmidt TGM, Skerra A. The random peptide library-assisted engineering of a C-terminal affinity peptide, useful for the detection and purification of a functional Ig Fv fragment. Protein Engineering 1993;6:109-122.
29. Murray GI, Burke MD, Ewen WB. Enzyme histochemistry on freeze-dried resin-embedded tissue. J Histochem Cytochem 1989;37:643-652.
30. Fransen L, van der Heyden B, Ruyschaert R, Fiers W. Recombinant tumor necrosis factor-α: Its effect and its synergism with interferon-γ on variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986;22:419-426.
31. Frankel HA, Glaser JH, Sly WS. Human b-glucuronidase. I. Recognition and uptake by animal fibroblasts suggests animal models for enzyme replacement studies. Pediatric Res 1977;11:811-822.
32. Bosslet K, Czech J, Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 1994;54:2152-2159.
33. Chen B-M, Chan L-Y, Wang S-M, Wu M-F, Chem JW, Roffler SR. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of glucuronide prodrug in rats. Int J Cancer 1997;73:392-402.
34. Gehrmann MC, Opper M, Sedlacek HH, Bosslet K, Czech J. Biochemical properties of recombinant human beta-glucuronidase synthesized in baby hamster kidney cells. J Biochem 1994;301:821-828.
35. Islam MR, Tomatsu S, Shab GN, Grubb JH, Jains S, Sly WS. Active site residues of human β-glucuronidase. J Biol Chem 1999;274:23451-23455.
36. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Meth 1983;64:313-320.
37. Marks TA, Woodman RJ, Geran RI, Billups LH, Madison RM. Characterization and responsiveness of the Madison 109 lung carcinoma to various antitumor agents. Cancer Treatment Reports 1977;61:1459-1470.
38. Hornick JL, Sharifi J, Khawli LA, Biela BH, Yuri A, Taylor CR, Epstein AL. A new chemically modified chimeric monoclonal antibody directed against DNA for the immunotherapy of solid tumors. Cancer Biother Biopharm 1998;13:255-264.
39. Schlesinger PH, Rodman JS, Doebber TW, Stahl PD, Lee YC, Stowell CD, Kuhlenschmidt TB. The role of extrahepatic tissues in the receptor mediated plasma clearance of glycoproteins terminated by mannose or N-acetylglucosamine. Biochem J 1980;192:597-606.
40. Cheng T-L, Chen B-M, Chan L-Y, Wu P-Y, Chern J-W, Roffler SR. Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs, Cancer Immunol Immunother 1997;44:305-316.
41. Stribbling SM, Martin J, Pedley RB, Boden JA, Sharma SK, Springer CJ. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Cancer Chemother Pharm 1997;40:277-284.
42. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumor angiogenesis. Cancer Res 1999;59:347-352.
43. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998;58:485-490.
44. Houba PHJ, Boven E, Haisma HJ. Improved characteristics of a human β-glucuronidase-antibody conjugate after deglycosylation for use in Antibody-Directed Enzyme Prodrug Therapy. Bioconj Chem 1996;7:606-611.
45. Buist MR, Kenemans P, den Hollander W, Vermorken JB, Molthoff CJM, Burger CW, Helmerhorst TJM, Baak JPA, Roos JC. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv 18 IgG and F(ab′)2 fragments in ovarian carcinoma patients. Cancer Res 1993;53:5413-5418.
46. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126-138.
47. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/gangciclovir enzyme/prodrug systems in human colorectal carcinoma cell line. Cancer Res 1995;55:4808-4812.
48. Perron P-J, Page M. Activation of methotrexate-phenylalanine by monoclonal antibody-carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Br J Cancer 1996;73:281-287.
49. Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Sakamoto, Yoshui H, Fukui H, Ikenaka K, Mullen CA, Tsuji T. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient antitumor effects and protective immunity in immunocompetent mice but not in athymic mice. Int J Cancer 1999;81:592-597.
50. Khawli L, Biela B, Hu P, Epstein A. Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybridoma Hybridomics 2003;22:1-9.